Results From Two Phase 2 Studies in XOMA (US) LLC's Gevokizumab Proof-of-Concept Program Are Very Encouraging and Compelling
Published: Oct 31, 2013
BERKELEY, Calif., Oct. 30, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced very encouraging results from two Phase 2 clinical studies that are part of the Company's broad gevokizumab proof-of-concept ("POC") program.
Help employers find you! Check out all the jobs and post your resume.